Rituxan (rituximab) - Roche
doxorubicin hydrochloride - Generic mfg.
vincristine - Generic mfg.
etoposide IV - Generic mfg.
cyclophosphamide - Generic mfg.
prednisone - Generic mfg.
Complex venous access in superior vena cava syndrome secondary to gray zone lymphoma, case report. (PubMed, Front Oncol) - Oct 2, 2026 - "A tunneled femoral catheter was therefore inserted to allow treatment initiation with rituximab plus dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, and prednisone (R-DA-EPOCH). Imaging-guided vascular assessment, multidisciplinary coordination, and adherence to international and national guidelines can enable safe delivery of curative-intent intensive chemotherapy, even in the setting of severe anatomical distortion and life-threatening complications. The case offers a visually documented, practical framework for managing venous access in complex anatomical conditions associated with superior vena cava syndrome." 
Journal • B Cell Lymphoma • Cardiovascular • Classical Hodgkin Lymphoma • Critical care • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • Pulmonary Embolism • Respiratory Diseases • Septic Shock
http://www.ncbi.nlm.nih.gov/pubmed/42819071
 
Bela Mrinakova; Maros Kunderlik; Martin Rázus; Michal Marko; Pavol Povinec; Vanda Repiská
 
Oct 2, 2026
 
Prev Next